How would you draft a package insert indication for a new lipid lowering drug that is proven more potent than atorvastatin

If you were a member of the drug development committee at a pharmaceutical sponsor, how would you draft a package insert indication for a new lipid lowering drug that is proven more potent than atorvastatin. The new drug is called lowerstatin.